SARS-CoV-2-Diagnostics

EPI-Dx

Epidemiological investigation on peptide signatures, immunity, genetic predisposition as well as changes in SARS-CoV-2.

Despite intensive research on all aspects of COVID-19 disease and pandemic, many questions of immunisation and epidemiology remain unanswered. In particular, questions about the development of immunity and infectivity are difficult to explore due to the fact that transmission appears to be particularly strong before symptoms appear. Reliable findings on the development of immunity are therefore of utmost importance for health policy action. Under which circumstances a mild or a severe course of COVID-19 is to be expected, outside of the so-called risk groups, is also still largely unknown. Genetic dispositions are equally unexplored. Can genetic variants explain the different courses (asymptomatic-mild, severe to fatal)? These and related questions will be investigated in the EPI-Dx project by collecting data from serological, genetic and PCR tests.

More information on EPI-Dx can be found on the project website.

Project partners

Microdiscovery GmbH

ATLAS Biolabs GmbH

in.vent Diagnostica GmbH

This Project was funded by the Federal Ministry of Education and Research

Grant Number: 03COV21

Further Projects

SARS-CoV-2-Diagnostics

DIRECT-Dx

Development of a sensitive antigen-based rapid test for the diagnostic of COVID-19
SARS-CoV-2-Diagnostics

TRAVEL-Dx

Development of a sensitive DNA-based rapid test for the diagnostics of COVID-19
SARS-CoV-2-Diagnostics

BEAD-Dx

Multiparameter test for the differential diagnostics of COVID-19
SARS-CoV-2-Diagnostics

VALIDATE-Dx

Appropriate and high quality study material is essential for the development of diagnostic tests.
SARS-CoV-2-Diagnostics

PEPTIDE-Dx

Can the identification of immunotopes serve as a basis for e.g. diagnostic tests?